Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: Re-treatment strategy (OCTOME Report 1)

Eye (Basingstoke)

Volumn 28, Issue 3, 2014, Pages 318-326

  Mathew, R ^a   Pearce, E ^a   Muniraju, R ^a   Abdul Hey, A ^a   Sivaprasad, S ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Macular oedema; Macular thickness; Optical coherence tomography; Ozurdex; Visual outcomes

Indexed keywords

DEXAMETHASONE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CENTRAL SUBFIELD THICKNESS; CHROMATIC SENSITIVITY; CLINICAL ARTICLE; CONTRAST SENSITIVITY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; ENDOPHTHALMITIS; EVALUATION STUDY; EXPLORATORY RESEARCH; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAVITREAL IMPLANT; IRIDOCYCLITIS; LOW LEVEL LASER THERAPY; MACULAR MORPHOLOGY; MACULAR THICKNESS; MALE; MICROPERIMETRY; MIDDLE AGED; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PSEUDOPHAKIA; READING; REPEAT PROCEDURE; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA EDEMA; RETINAL VASCULAR DISEASE; RETREATMENT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; VERY ELDERLY; VISION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE;

EID: 84896359055     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.287     Document Type: Article

References (17)

1. Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci 2011; 52(5): 2741-2748.
2. Abe T, Hayasaka S, Nagaki Y, Kadoi C, Matsumoto M, Hayasaka Y. Pseudophakic cystoid macular edema treated with high-dose intravenous methylprednisolone. J Cataract Refract Surg 1999; 25(9): 1286-1288.
3. Binz N, Graham CE, Simpson K, Lai YK, Shen WY, Lai CM et al. Long-Term effect of therapeutic laser photocoagulation on gene expression in the eye. Faseb J 2006; 20(2): 383-385.
4. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127(9): 1115-1128.
5. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109(5): 920-927.
6. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001; 29(1): 2-6.
7. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121(1): 57-61.
8. Loewenstein A, Goldstein M. Intravitreal triamcinolone acetonide for diabetic macula edema. Isr Med Assoc J 2006; 8(6): 426-427.
9. Haller JA, Bandello F, Belfort Jr. R, Blumenkranz MS, Gillies M, Heier J et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117(6): 1134-1146.
10. Haller JA, Bandello F, Belfort Jr. R, Blumenkranz MS, Gillies M, Heier J et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelvemonth study results. Ophthalmology 2011; 118(12): 2453-2460.
11. Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114(3): 525-536.
12. Legge GE, Ross JA, Luebker A, LaMay JM. Psychophysics of reading. VIII. The Minnesota Low-Vision Reading Test. Optom Vis Sci 1989; 66(12): 843-853.
13. Connolly DM, Barbur JL, Hosking SL, Moorhead IR. Mild hypoxia impairs chromatic sensitivity in the mesopic range. Invest Ophthalmol Vis Sci 2008; 49(2): 820-827.
14. Fujii GY, De Juan Jr. E, Humayun MS, Sunness JS, Chang TS, Rossi JV. Characteristics of visual loss by scanning laser ophthalmoscope microperimetry in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003; 136(6): 1067-1078.
15. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52(1): 80-86.
16. Audren F, Tod M, Massin P, Benosman R, Haouchine B, Erginay A et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004; 45(10): 3435-3441.
17. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G et al. Repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmologica 2013; 229(1): 21-25.